C
Chester V. Oddis
Researcher at University of Pittsburgh
Publications - 169
Citations - 13130
Chester V. Oddis is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Myositis & Dermatomyositis. The author has an hindex of 54, co-authored 157 publications receiving 10948 citations. Previous affiliations of Chester V. Oddis include Tokai University.
Papers
More filters
Journal ArticleDOI
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis
Daniel O. Clegg,Domenic J. Reda,Crystal L. Harris,Marguerite A. Klein,James R. O'Dell,Michele Hooper,John D. Bradley,Clifton O. Bingham,Michael H. Weisman,Christopher G. Jackson,Nancy E Lane,John J. Cush,Larry W. Moreland,H. Ralph Schumacher,Chester V. Oddis,Frederick Wolfe,Jerry A. Molitor,David E. Yocum,Thomas J. Schnitzer,Daniel E. Furst,Allen D. Sawitzke,Helen Shi,Kenneth D. Brandt,Roland W. Moskowitz,H. James Williams +24 more
TL;DR: The GAIT trial as discussed by the authors evaluated the efficacy and safety of glucosamine and chondroitin sulfate as a treatment for knee pain from osteoarthritis in 1583 patients.
Journal ArticleDOI
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups
Ingrid E. Lundberg,Anna Tjärnlund,Matteo Bottai,Victoria P. Werth,Clarissa Pilkington,Marianne de Visser,Lars Alfredsson,Anthony A. Amato,Richard J. Barohn,Matthew H. Liang,Jasvinder A. Singh,Jasvinder A. Singh,Rohit Aggarwal,Snjolaug Arnardottir,Hector Chinoy,Robert G. Cooper,Katalin Dankó,Mazen M. Dimachkie,Brian M. Feldman,Ignacio García-De La Torre,Patrick Gordon,Taichi Hayashi,James D. Katz,Hitoshi Kohsaka,Peter A. Lachenbruch,Bianca A. Lang,Yuhui Li,Chester V. Oddis,Marzena Olesińska,Ann M. Reed,Lidia Rutkowska-Sak,Helga Sanner,Albert Selva-O'Callaghan,Yeong Wook Song,Jiri Vencovsky,Steven R. Ytterberg,Frederick W. Miller,Frederick W. Miller,Lisa G. Rider,Lisa G. Rider +39 more
TL;DR: New classification criteria for IIM have been endorsed by international rheumatology, dermatology, neurology and paediatric groups, and have been partially validated and generally perform better than existing criteria.
Journal ArticleDOI
Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis
Shinji Sato,Michito Hirakata,Masataka Kuwana,Akira Suwa,Shinichi Inada,Tsuneyo Mimori,Takeji Nishikawa,Chester V. Oddis,Yasuo Ikeda +8 more
TL;DR: Results indicate that the presence of anti-CADM-140 autoantibodies may be a novel marker for C-ADM, and further attention should be directed to the detection of rapidly progressive ILD in those patients with anti- CADM.
Journal ArticleDOI
2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups.
Ingrid E. Lundberg,Anna Tjärnlund,Matteo Bottai,Victoria P. Werth,Clarissa Pilkington,Marianne de Visser,Lars Alfredsson,Anthony A. Amato,Richard J. Barohn,Matthew H. Liang,Jasvinder A. Singh,Rohit Aggarwal,Snjolaug Arnardottir,Hector Chinoy,Robert G. Cooper,Katalin Dankó,Mazen M. Dimachkie,Brian M. Feldman,Ignacio García-De La Torre,Patrick Gordon,Taichi Hayashi,James D. Katz,Hitoshi Kohsaka,Peter A. Lachenbruch,Bianca A. Lang,Yuhui Li,Chester V. Oddis,Marzena Olesińska,Ann M. Reed,Lidia Rutkowska-Sak,Helga Sanner,Albert Selva-O'Callaghan,Yeong Wook Song,Jiri Vencovsky,Steven R. Ytterberg,Frederick W. Miller,Lisa G. Rider,Repository,Ireland +38 more
TL;DR: To develop and validate new classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIM) and their major subgroups.
Journal ArticleDOI
Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis: A Randomized, Placebo-phase Trial
Chester V. Oddis,Ann M. Reed,Rohit Aggarwal,Lisa G. Rider,Dana P. Ascherman,Marc C. Levesque,Richard J. Barohn,Brian M. Feldman,Michael O. Harris-Love,Diane Koontz,Noreen Fertig,Stephanie S. Kelley,Sherrie L. Pryber,Frederick W. Miller,Howard E. Rockette +14 more
TL;DR: Although there were no significant differences in the 2 treatment arms for the primary and secondary end points, 83% of adult and juvenile myositis patients with refractory disease met the DOI, and individual CSMs improved in both groups throughout the 44-week trial.